About this document
Frigerio 2021 by garbeliniluan is a document available to read on EtoBox.
This review evaluates the anti-PSMA antibody fragment scFvD2B as a theranostic tool for prostate cancer (PCa), highlighting its potential for imaging and therapy due to its high stability and specific tumor targeting. The study discusses the biomolecular characteristics, cross-reactivity, and therapeutic efficacy of scFvD2B in preclinical models, demonstrating its capability to achieve optimal tumor-to-background ratios and redirect immune cells to PSMA-positive tumors. Overall, scFvD2B shows promise in add
- Author
- garbeliniluan
- Language
- EN